CryoPort, Inc. (CYRX)
| Market Cap | 3.15B |
| Revenue (ttm) | 39.58M |
| Net Income (ttm) | -22.11M |
| Shares Out | 39.14M |
| EPS (ttm) | -0.59 |
| PE Ratio | n/a |
| Forward PE | 263.16 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $69.10 |
| Previous Close | $67.31 |
| Change ($) | 1.79 |
| Change (%) | 2.66% |
| Day's Open | 66.01 |
| Day's Range | 63.80 - 72.81 |
| Day's Volume | 917,843 |
| 52-Week Range | 13.56 - 82.11 |
NASHVILLE, Tenn., Jan. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life scien...
NASHVILLE, Tenn., Jan. 20, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life scien...
NASHVILLE, Tenn., Jan. 19, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life scien...
Where investors are putting money to work in the Covid vaccine supply chain
CNBC's "Halftime Report" team is joined by Kate Kelly of The New York Times to discuss where investors are putting money along the vaccine supply chain, including cold storage.
With the approval of Yescarta and Kymriah in recent years, you are now seeing unprecedented growth in the CAR-T industry. Logistic providers that support CAR-T and gene therapies are profiting...
Logistics of Vaccine Distribution Challenging: Cryoport CEO
Dec.01 -- Cryoport Inc. looks forward to the opportunity to participate in the distribution of the Covid-19 vaccines and admits the logistics will be challenging, Chief Executive Officer Jerre...
Cryoport is a strong cold chain platform focused on the fast-growing cell and gene therapy end-market. Company has demonstrated strong execution through COVID and, with recent acquisitions, wi...
Cryoport's operating model remains insulated via key differentiators in the thermoregulatory logistics domain, with cloud-based integration along the audit chain. Linking with larger players i...
Excited about the Covid-19 vaccines from Pfizer and Moderna? You'll be waiting a long time unless the vaccines can be shipped at 94 degrees below zero.
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q3 2020 Results - Earnings Call Transcript
NASHVILLE, Oct. 29, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in life sciences solutions, today announced that the Company will report f...
NASHVILLE, Tenn., Oct. 1, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), the life sciences industry's preeminent partner for temperature-controlled supply ch...
Final Trades: CrowdStrike, Cryoport, Industrials & more
The "Halftime Report" traders give their top picks to watch for the second half.
How Cryoport plays a role in the coronavirus fight
CNBC's "Power Lunch" team talks about Cryoport's stock rally with Cryoport CEO Jerrell Shelton.
Cryoport is acquiring Chart's cryobiological business and getting a big boost from one of the giants in private equity.
Cryoport (CYRX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
NASHVILLE, Tenn., Aug. 25, 2020 /PRNewswire/ -- Cryoport, Inc.
NASHVILLE, Tenn., Aug. 21, 2020 /PRNewswire/ -- Cryoport, Inc.
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q2 2020 Results - Earnings Call Transcript
NASHVILLE, Tenn., Aug. 6, 2020 /PRNewswire/ -- Cryoport, Inc.
NASHVILLE, Tenn. and TOKYO, Aug.
NASHVILLE, Tenn., Aug. 3, 2020 /PRNewswire/ -- Cryoport, Inc.
NASHVILLE, Tenn., May 21, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport") today announced the pricing on May 20, 2020 of its offering of $100.0 million in aggregate principal a...
NASHVILLE, Tenn., May 19, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport") today announced its intention to offer, subject to market and other conditions, $100.0 million in aggr...
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q1 2020 Results - Earnings Call Transcript
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q4 2019 Results - Earnings Call Transcript
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q3 2019 Results - Earnings Call Transcript
Cryoport's (CYRX) CEO Jerry Shelton on Q2 2019 Results - Earnings Call Transcript
Both companies operate in the same market and are of similar size and produce comparable growth rates, yet CryoPort sells at 2.5x the valuation of BioLife.
Chimeric Antigen Receptor/T-Cell Receptor (CAR-T) is powering a fundamental shift for treating deadly cancers.
Cryoport's (CYRX) CEO Jerry Shelton on Q1 2019 Results - Earnings Call Transcript
CYRX earnings call for the period ending December 31, 2018.
About CYRX
Cryoport provides temperature-controlled logistics and biostorage services to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Global Logistics Solutions and Global Bioservices. The Global Logistics Solutions segment offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resol... [Read more...]
| Industry Integrated Freight & Logistics | Founded 1999 |
| CEO Jerrell W. Shelton | Employees 105 |
| Stock Exchange NASDAQ | Ticker Symbol CYRX |
Financial Performance
In 2019, CryoPort's revenue was $33.94 million, an increase of 72.94% compared to the previous year's $19.63 million. Losses were -$18.33 million, 91.8% more than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for CryoPort stock is "Strong Buy." The 12-month stock price forecast is 63.29, which is a decrease of -8.41% from the latest price.